Dyadic International (NASDAQ:DYAI) Share Price Crosses Below 50 Day Moving Average – What’s Next?

Posted by George Bondi on May 22nd, 2026

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.81 and traded as low as $0.7251. Dyadic International shares last traded at $0.7376, with a volume of 12,497 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Dyadic International presently has an average rating of “Hold” and an average target price of $3.00.

Read Our Latest Research Report on DYAI

Dyadic International Trading Up 2.6%

The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm has a market cap of $27.67 million, a price-to-earnings ratio of -3.30 and a beta of 1.18. The business’s fifty day moving average is $0.81 and its two-hundred day moving average is $0.87.

Dyadic International (NASDAQ:DYAI – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. Equities analysts anticipate that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of Dyadic International

A number of hedge funds and other institutional investors have recently modified their holdings of DYAI. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the period. Marathon Capital Management acquired a new stake in Dyadic International during the 3rd quarter worth $41,000. Geode Capital Management LLC grew its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares during the period. Truist Financial Corp grew its holdings in Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 76,200 shares during the period. Finally, Landscape Capital Management L.L.C. acquired a new stake in Dyadic International during the 3rd quarter worth $190,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

About Dyadic International

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.